Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | BCL9 | O00512 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7989561 | 0.87 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL15459741 | 0.87 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL2232343 | 0.86 | HTR2A (0.48) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL2233659 | 0.85 | HTR2A (0.52) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL1059539 | 0.84 | HTR2A (0.60) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL2235530 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL19457107 | 0.82 | HTR2A (0.52) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL23922815 | 0.82 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL21097121 | 0.82 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL21098059 | 0.82 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049514-B1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090318432-A1 | Nitrate esters of aminoalcohols | SPEEDEL EXPERIMENTA AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-2061751-A1 | NITRATE ESTERS OF AMINOALCOHOLS | Novartis Ag (CH) | 2009-05-27 | — | — | EP | disclosed |
| EP-2049514-A1 | NITRATE ESTERS OF PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008031811-A1 | NITRATE ESTERS OF AMINOALCOHOLS | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008017685-A1 | NITRATE ESTERS OF PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318432-A1 | Nitrate esters of aminoalcohols | NOS2, NOS1, NOS3 | HTR2A 3879/4885GAA 3099/4885BCL9 4314/4885 |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | HTR2A 2234/4885GAA 2901/4885BCL9 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.